Analyst Price Target is $29.50
▲ +172.90% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for FibroGen in the last 3 months. The average price target is $29.50, with a high forecast of $58.00 and a low forecast of $11.00. The average price target represents a 172.90% upside from the last price of $10.81.
Current Consensus is
The current consensus among 10 polled investment analysts is to hold stock in FibroGen. This Hold consensus rating has held steady for over two years.
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.